Valsartan Litigation and MDL

In July 2018, the United States Food and Drug Administration alerted health case 

professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan due to the discovery that it contained N-NitrosoDiMethylamine (NDMA).

Valsartan is an oral blood pressure medication that has been linked to causing cancer, it is also given to patients who have experienced heart attacks or heart failure. Valsartan is an angiotensin II receptor antigen; this is a class of medication that works by blocking the action of certain natural substances that tighten the blood vessels. This ultimately relaxes the blood vessels and puts less strain on the heart.  

Lawsuits allege that from 2012 to 2018 batches of Valsartan were contaminated with NDMA, a probable carcinogen. The presence of NDMA, according to the FDA, may increase the risk of developing certain kinds of cancer including liver, kidney, colorectal, intestinal, stomach, bladder, and/or pancreas. These lawsuits also allege that drug manufacturers willfully disregarded the required safety procedures at the plant where the contamination occurred. This contaminant went undiscovered for years until it was revealed by random testing. 

If you or someone you know have received a diagnosis after taking Valsartan, it is important to contact Oliver Law Office to evaluate your case. Because drug manufacturers have large amounts of money to spend on attorneys and law firms with large resources, it is often difficult or intimidating to bring suit alone. 

Valsartan FDA updates on recall and NDMA contamination